DMAC
NASDAQ · Biotechnology
Diamedica Therapeutics Inc
$6.34
-0.17 (-2.61%)
Open$6.55
Previous Close$6.51
Day High$6.55
Day Low$6.26
52W High$10.42
52W Low$4.39
Volume—
Avg Volume169.9K
Market Cap363.71M
P/E Ratio—
EPS$-0.71
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
-34.4% upside
Current
$6.34
$6.34
Target
$4.16
$4.16
$2.49
$4.16 avg
$4.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 75.08M | 73.96M | 78.61M |
| Net Income | 7.50M | 6.55M | 6.83M |
| Profit Margin | 10.0% | 8.9% | 8.7% |
| EBITDA | 9.74M | 10.19M | 9.65M |
| Free Cash Flow | 6.22M | 6.24M | 10.05M |
| Rev Growth | +22.4% | +12.6% | +21.2% |
| Debt/Equity | 0.48 | 0.47 | 0.46 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |